B-Lymphoid Blast Phase–Chronic Myeloid Leukemia: Current Therapeutics

Binoy Yohannan, Binsah George

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

Blast crisis (BC) is one of the most dreaded complications of chronic myeloid leukemia (CML). Fortunately, the incidence of BC has diminished markedly in the BCR-ABL tyrosine kinase inhibitor (TKI) era. The primary objective of initial treatment in BC is to achieve a second chronic phase (CP) and to proceed to an allogeneic stem cell transplantation (SCT) in eligible patients. The clinical outcome of patients with CML BC remains unsatisfactory, even with highly potent TKIs, as remissions are short lived and there is an unmet need for novel therapies. We provide a comprehensive summary reviewing the current management of Lymphoid BC.

Original languageEnglish (US)
Article number11836
JournalInternational journal of molecular sciences
Volume23
Issue number19
DOIs
StatePublished - Oct 2022
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2022 by the authors.

Keywords

  • chronic myeloid leukemia
  • lymphoid blast crisis
  • Philadelphia chromosome
  • tyrosine kinase inhibitors

Fingerprint

Dive into the research topics of 'B-Lymphoid Blast Phase–Chronic Myeloid Leukemia: Current Therapeutics'. Together they form a unique fingerprint.

Cite this